Mantle cell lymphoma surgery: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(4 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{ Mantle cell lymphoma }}
{{Mantle cell lymphoma }}


{{CMG}}; {{AE}} {{AS}}
{{CMG}}; {{AE}} {{Akram}} {{AS}}


==Overview==
==Overview==
Surgical intervention is not recommended for the management of [disease name].
OR
Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]
OR
The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].
OR
The feasibility of surgery depends on the stage of [malignancy] at diagnosis.
OR
Surgery is the mainstay of treatment for [disease or malignancy].


The mainstay of treatment for mantle cell lymphoma is [[medical]] [[therapy]]. However, [[Surgery|surgical]] [[therapy]] has proven [[Cure|curative]] in a case of [[Mantle cell lymphoma|MCL]] with a single protruding [[lesion]] presenting as [[intussusception]].
==Indications==
==Indications==
* The mainstay of treatment for mantle cell lymphoma is [[Medicine|medical]] [[therapy]]. However, [[Surgery|surgical]] [[therapy]] has proven [[Cure|curative]] in a case of [[Mantle cell lymphoma|MCL]] with a single protruding [[lesion]] presenting as [[intussusception]].<ref>{{Cite journal
| author = [[Katsunori Matsueda]], [[Tatsuya Toyokawa]], [[Masahiro Sakata]], [[Isao Fujita]] & [[Jouichiro Horii]]
| title = Mantle Cell Lymphoma with a Single Protruding Lesion as the Cause of Intussusception
| journal = [[Internal medicine (Tokyo, Japan)]]
| volume = 57
| issue = 12
| pages = 1751–1755
| year = 2018
| month = June
| doi = 10.2169/internalmedicine.0199-17
| pmid = 29434133
}}</ref>
   


*Surgical intervention is not recommended for the management of [disease name].
OR
*Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either:
**[Indication 1]
**[Indication 2]
**[Indication 3]
*The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either:
**[Indication 1]
**[Indication 2]
**[Indication 3]
==Surgery==
*The feasibility of surgery depends on the stage of [malignancy] at diagnosis.
OR
*Surgery is the mainstay of treatment for [disease or malignancy].


==Contraindications==
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 20:23, 7 January 2019

Mantle cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mantle cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mantle cell lymphoma surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mantle cell lymphoma surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mantle cell lymphoma surgery

on Mantle cell lymphoma surgery

Mantle cell lymphoma surgery in the news

Blogs on Mantle cell lymphoma surgery

Directions to Hospitals Treating Mantle cell lymphoma

Risk calculators and risk factors for Mantle cell lymphoma surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2] Sowminya Arikapudi, M.B,B.S. [3]

Overview

The mainstay of treatment for mantle cell lymphoma is medical therapy. However, surgical therapy has proven curative in a case of MCL with a single protruding lesion presenting as intussusception.

Indications


References

  1. Katsunori Matsueda, Tatsuya Toyokawa, Masahiro Sakata, Isao Fujita & Jouichiro Horii (2018). "Mantle Cell Lymphoma with a Single Protruding Lesion as the Cause of Intussusception". Internal medicine (Tokyo, Japan). 57 (12): 1751–1755. doi:10.2169/internalmedicine.0199-17. PMID 29434133. Unknown parameter |month= ignored (help)

Template:Hematology

Template:WH Template:WS